PDF-Paediatric Antiretroviral Drug Optimization PADO Meeting 4

1012December2018GenevaSwitzerlandMeetingreportAnnex 1 Meeting agendaDay 1 Monday 10 December 201813301345Registration13451415Welcome and introductionsMeg Doherty Overview of meeting objectives and age. in paediatric population: what may be extrapolated from findings in adults?. Henning H. Blume, PhD. SocraTec R&D. ,. . Oberursel/Germany. . Concepts in Drug Research and Development. henning.blume@socratec-pharma.de. DEEP. multinational and multicultural experience. Adriana . Ceci. DEEP . Scientific Coordinator, . and . member of PDCO-EMA. 16 Partners . 18 recruiting centres from 7 Countries:. EU: Cyprus, Greece, . Module 10:. Pharmacovigilance. Background – definitions. Timeline of pharmacovigilance for a drug from development (pre-market) to post-marketing use. Burden of adverse drug reactions in children. Number of pharmacoepidemiological safety studies in children (Osokogu et al, 2016). & HCV . Therapy. Larry Pineda, . PharmD. , . PhC. , BCPS, AAHIVP. Visiting Assistant Professor. UNM College of Pharmacy. Conflicts of Interest Disclosure. No conflicts of interest. 2. Learning Objectives – Pharmacist. Action. Improving Access to Optimized Treatment . for Children . Living with HIV. Melbourne, 22 July 2014. Marc Lallemant & Janice Lee. DNDi. mlallemant@dndi.org. Malaria. Leishmaniasis. ACTIVITY CODE . TD342. Antiretroviral Medications: . What . you need to know. Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP. Associate Professor, Department of Pharmacy Practice. Geneva, March 19 - 20 , 2015 1 | Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato, Nathan Ford Update on CADO/PADO: what are the challenges in using the current guidelines an *\n

\b\n\t\t
\t$

\n\n
$\b
\t\b$
 Performance Analysis, Diagnostic and Optimisation (PADO)How to Improve Efficiency First Step: low hanging fruitsImprove efficiency by improving operationand maintenanceNext Steps:Audit or „map&# First Paediatric Antituberculosis Drug Optimization Meeting (PADO - TB 1) Date: 14 - 15 February 2019 Meeting room CDS65, fourth floor of the WHO D - building/UNAIDS building, Geneva, Switzerland 2 E NOTEMake sure the combined number and length of all named services advertisedin the PADO packet does not exceed the MTU size of the PPPoE underlying interfaceTo enable advertisement of named services PADO-Dr Martina Penazzato MD MSc PhDPaediatricHIV lead HIV and Hepatitis Department World Health Organization Geneva SwitzerlandThe development of pediatric products lags unacceptably behind that of a With Emergence of Comorbidities. Roger J. . Bedimo. , MD. Professor of Medicine. University of Texas Southwestern Medical Center. Dallas, TX. Learning Objectives. On completion of this presentation, learners will be able to:. Constance A. Benson, MD. Professor of Medicine and Global Public Health. University of California San Diego. La Jolla, California. Goals for the Workshop. To describe the potential benefits of long-acting antiretroviral drugs (ARVs) for treatment and prevention of HIV infection.